CEPT Inhibitors Finally Show Potential With Obicetrapib

After many setbacks, the potential for CETP inhibition to significantly improve cholesterol levels and target attainment has been shown with obicetrapib in the ROSE trial.
Medscape Medical News

source https://www.medscape.com/viewarticle/974786?src=rss

Comments

Popular posts from this blog

New AAFP practice guideline sets blood pressure targets for adults with hypertension

RA and RA-ILD Linked to Higher Lung Cancer Risk

A Large Multicenter Prospective Study of Community-Onset Healthcare Associated Bacteremic Urinary Tract Infections in the Era of Multidrug Resistance: Even Worse than Hospital Acquired Infections?